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ABSTRACT.
Purpose: As a progressive condition, glaucoma may impair health-related quality of life (HRQoL), due to vision loss and
other factors. This study evaluated HRQoL in a cohort of patients treated for primary open-angle glaucoma (POAG) and
assessed its association with clinical features.
Methods: This was an Italian, multicentre, cross-sectional, observational study with the subgroup of newly diagnosed
patients with POAG prospectively followed up for one year. Patients with previous or new diagnosis (or strong clinical
suspicion) of POAG aged >18 years were considered eligible. Information was collected on demographic characteristics,
medical history, clinical presentation and POAG treatments. HRQoL was measured using the 25-item National Eye
Institute Visual Function Questionnaire (NEI-VFQ-25) and Glaucoma Symptom Scale (GSS). Subscale and total scores
were obtained and a Pearson correlation coeﬃcient between instruments’ scores calculated.
Results: A total of 3227 patients were enrolled from 2012 to 2013 and 3169 were analysed. Mean age was 66.9 years. A
total of 93.8% had a previous diagnosis (median duration: 8.0 years). Median values for mean deviation and pattern
standard deviation were 3.9 and 3.6 dB, respectively. Mean scores on most subscales of the NEI-VFQ-25 exceeded 75.0
and mean GSS subscale scores ranged between 70.8 and 79.7 (with a total mean score of 74.8). HRQoL scores on both
scales were signiﬁcantly inversely associated with POAG severity.
Conclusion: In this large sample of Italians treated for POAG, disease severity was limited and HRQoL scores were high.
QoL decreased with advancing disease severity. These ﬁndings conﬁrm the role of vision loss in impairing QoL in POAG,
underlying the importance of timely detection and appropriate treatment.
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Introduction
Glaucoma is a leading cause of
irreversible visual loss worldwide
(Giangiacomo 2009). Data from popu-
lation-based surveys indicate that
1.86% of adults ≥40 years old has
glaucoma, which equates to 60 mil-
lion people worldwide being aﬀected
and 8.4 million being bilaterally blind
(Giangiacomo 2009; Quigley 2011). Of
several types of glaucoma, primary
open-angle glaucoma (POAG) is the
most common. Populations of Euro-
pean ancestry are particularly aﬀected
(Giangiacomo 2009; Kwon et al. 2009).
In Italy, a population-based survey
reported a POAG prevalence of 1.4%
in a population of 5000 adults of rural
northern Italy (Bonomi et al. 1998).
As a chronic and progressive condi-
tion, POAG can signiﬁcantly aﬀect
quality of life (QoL). Visual impair-
ment, associated with limitation of
daily function and loss of autonomy,
may lead to or exacerbate depression,
loneliness and anxiety (Dodds 1991;
Hinds et al. 2003), especially in the
elderly (Baker & Winyard 1998).
However, other non-visual factors,
such as distress caused by the knowl-
edge of having a blinding illness, cost
of treatment or problems and adverse
reactions to glaucoma therapies, have
also been frequently implicated as fac-
tors negatively impacting QoL in these
patients (Stuck et al. 1999; Odberg
et al. 2001a; Spaeth et al. 2006).
Health-related QoL (HRQoL) mea-
sures can be indicative of the disease-
related burden experienced by the
patient, and its importance is increas-
ingly recognized. In fact, the very aim
of glaucoma management is the
patient’s autonomy and preservation
of QoL at a sustainable cost (European
Glaucoma Society 2014).
Compared to the state of evidence
on the impact of other chronic diseases
on QoL, the existing literature on
glaucoma-related QoL is limited (Mills
et al. 2009). Moreover, the relative role
of diﬀerent factors in aﬀecting QoL in
patients with POAG merits investiga-
tion and requires a suﬃciently numer-
ous patient population.
The investigators of the Italian
Study Group on QoL in Glaucoma
have designed a study with both a
cross-sectional and a prospective part.
The aim of the cross-sectional part was
the evaluation of HRQoL in a large
cohort of patients with POAG, and the
assessment of the contribution of
socio-demographic and clinical fea-
tures. Vice versa, the prospective part
aimed to assess the changes in QoL
measures over 12-month follow-up.
This ﬁrst report describes the study
design, sample characteristics and over-
all results on QoL of the cross-sectional
cohort study.
Methods
This was an Italian, multicentre obser-
vational study. In an eﬀort to capture a
cohort representative of the population
of Italian patients with POAG, the
ophthalmic centres invited to partici-
pate comprised of both academic and
non-academic institutions with a
nationwide geographical distribution.
The study was conducted in accor-
dance with the tenets of the Declara-
tion of Helsinki and the Guidelines for
Good Clinical Practice. The institu-
tional review board of each partici-
pating centre approved the protocol.
The participants gave informed con-
sent after the nature and purpose of
the survey were fully explained. Data
were handled according to current
Italian legislation on observational
studies.
Patients and procedures
Patients with a previous or new diagno-
sis (or strong clinical suspicion) of
Table 1. Participating centre distribution and accrual.
Centre Patients
Academic/
non-academic City
Geographical
region
University of ‘Magna Graecia’ 419 Academic Catanzaro South/Isles
A.O.U. Senese Ospedale Santa
Maria delle Scotte, Universita
di Siena
336 Academic Siena Centre
Fondazione IRCCS Istituto di
Ricovero e Cura a Carattere
Scientiﬁco Policlinico San
Matteo
294 Non-academic Pavia North-west
IRCCS Istituto di Ricovero e
Cura a Carattere Scientiﬁco
Istituto Auxologico Italiano
265 Non-academic Milano North-west
University of Torino 253 Academic Torino North-west
University of Brescia 205 Academic Brescia North-west
Fondazione IRCCS Istituto di
Ricovero e Cura a Carattere
Scientiﬁco Ca’ Granda
Ospedale Maggiore
Policlinico
204 Academic Milano North-west
A.O.U. di Parma 200 Academic Parma North-east
A.O.U. Cagliari – Ospedale
Civile San Giovanni di Dio
183 Academic Cagliari South/Isles
A.O.U. ‘Policlinico Vittorio
Emanuele’ P.O. Gaspare
Rodolico
126 Academic Catania South/Isles
A.O.U. ‘Ospedale Maggiore’ 114 Academic Trieste North-east
A.O. Arcispedale Santa Maria
Nuova-IRCCS
107 Non-academic Reggio Emilia North-east
Universita Tor Vergata,
Fondazione Policlinico Tor
Vergata
100 Academic Rome Centre
A.O. S. Paolo 100 Academic Milan North-west
A.O.U. Policlinico 98 Academic Bari South/Isles
Ospedale Clinicizzato SS.
Annunziata
64 Non-academic Chieti South/Isles
A.O.U. Policlinico S. Orsola
Malpighi
36 Academic Bologna North-east
A.O. di Desenzano del Garda 30 Non-academic Desenzano
del Garda
North-west
Dipartimento SPES Universita
del Molise
20 Academic Campobasso South/Isles
IRCCS AOU San Martino –
IST
15 Academic Genova North-west
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POAG were approached during regular
clinic visits and screened for participa-
tion in this study. To be eligible for
participation, patients needed to be
18 years or older and to be able to
comprehend and reply to the self-admin-
istered study instruments. Concurrent
participation in another clinical trial was
considered an exclusion criterion.
Patients were considered eligible for
inclusion if they had typical glaucoma-
tous optic nerve head damage, that is
focal or generalized (or both) neu-
roretinal rim thinning or cup/disc ratio
asymmetry >2 in the absence of other
neurodegenerative conditions. The
presence of typical glaucomatous visual
ﬁeld defects was not a prerequisite for
inclusion if clinical judgment was
strongly in favour of glaucoma (e.g.
high IOP, optic disc haemorrhages,
retinal nerve ﬁbre layer defects)
(Topouzis et al. 2008).
Eligible patients underwent a com-
prehensive ocular examination and
treatment was started or continued, as
clinically indicated. Demographic char-
acteristics, medical and ophthalmic
history, and information on surgical
and medical treatments of POAG were
collected and QoL questionnaires
administered. Glaucoma severity was
classiﬁed in all patients according to
Glaucoma Staging System 2 (Brusini &
Filacorda 2006). Only reliable visual
ﬁeld data (i.e. visual ﬁelds were consid-
ered reliable if false-positive responses
were fewer than 15% and a clear blind
spot could be seen in the visual ﬁeld
printouts, threshold value <10 decibel
[dB]) were included in the analysis.
Study instruments
Study HRQoL instruments comprised
of the validated Italian versions of the
25-item National Eye Institute Visual
Function Questionnaire (NEI-VFQ-25)
(Rossi et al. 2003) and the Glaucoma
Symptom Scale (GSS) questionnaire
(Rossi et al. 2013).
GSS (Lee et al. 1998), a glaucoma-
speciﬁc instrument, includes 10 items
grouped into two domains (Symp-6
for non-visual symptoms and Func-4
for visual symptoms). Each eye is
assessed separately for the presence
of ten speciﬁc symptoms, using a 0–
100 scale, where zero represents the
highest grade of disturbance and 100
indicates the symptom’s absence. The
subscale score is the unweighted aver-
age of subscale score of each eye.
Similarly, the total GSS score is the
mean of the 10 subscale scores. Hence,
GSS scores can be calculated as aver-
age between the two eyes or for each
eye separately.
NEI-VFQ-25 is a self-administered,
25-item, 12-subscale questionnaire
designed to measure vision-dependent
function and used to assess impact of
diﬀerent of ocular conditions on
HRQoL (Mangione et al. 2001). Each
subscale receives a score of 0–100,
where higher scores reﬂect better
Table 2. Socio-demographic characteristics of the eligible patients (N = 3169).
Age – years
Mean (SD) 66.9 (12.1)
Min–max values 18.6–100.6
Female sex – N (%) 1578 (49.8)
Race – N (%)
Caucasian 3147 (99.3)
Black 16 (0.5)
Asian 6 (0.2)
Educational – N (%)*
Illiterate 24 (0.8)
Primary school 917 (29.0)
Secondary school 899 (28.4)
High school 976 (30.8)
University degree 352 (11.1)
Housing status – N (%)*
In family 2520 (79.5)
Alone 534 (16.9)
With other people 114 (3.6)
Employment status – N (%)*
Retired 1910 (60.3)
Active 749 (23.6)
Housewife 410 (12.9)
Unemployed 67 (2.1)
Student 25 (0.8)
Other 7 (0.2)
SD = standard deviation; min–max = minimum–maximum.
* One missing value.
Table 3. Clinical characteristics of the eligible patients (N = 3169).
At ﬁrst diagnosis – N (%) 197 (6.2)
Years from diagnosis*
Median (Q1, Q3) 8.0 (4.0, 13.0)
Min–max values 0.2–57.0
Bilateral glaucoma – N (%) 3022 (95.4)
Mean deviation – decibel‡
Median (Q1, Q3) 3.90 (8.50,1.55)
Min–max values 42.35 to +3.70
PSD – decibel‡
Median (Q1, Q3) 3.60 (2.01, 6.65)
Min–max values 0.33–25.80
Visual Field Index – %‡
Median (Q1, Q3) 93.0 (80.5, 97.5)
Min–max values 0–100
Severity of disease – N (%)†,‡
Stage 0 12 (0.4)
Borderline 394 (12.6)
Stage 1 576 (18.4)
Stage 2 657 (21.0)
Stage 3 477 (15.3)
Stage 4 431 (13.8)
Stage 5 575 (18.4)
* In previously diagnosed patients only. One value missing.
† Worst eye in case of bilateral glaucoma.
‡ Missing values.
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vision-related QoL. The global score is
the mean of the 11 subscale scores,
excluding the general health item.
Statistical consideration
In Italy, there are currently approxi-
mately 500 000 patients with POAG
managed in 50 specialized glaucoma
centres (Cedrone et al. 2008). Based on
this assumption, a cohort of at least
3000 patients enrolled by approxi-
mately 20 ophthalmic centres was con-
sidered representative of the Italian
population of patients with POAG.
Descriptive summary statistics are
presented as mean, standard deviation,
minimum and maximum values, and/or
median, 25th and 75th percentiles (Q1,
Q3), for continuous variables. Absolute
frequency and percentage were used for
categorical variables. The Spearman
rank correlation test was used to study
the strength of correlation between
each single subscale and the mean total
scores of the two study instruments.
Correlation coeﬃcients >0.5 were con-
sidered large, 0.5–0.3 moderate, 0.3–0.1
small and smaller than 0.1 insubstan-
tial (Cohen 1988).
For all analyses, we have considered
patients as unit of analysis; for GSS
Questionnaire, the mean of the two
eyes was used.
The association between QoL sub-
scales and the severity of glaucoma, as
expressed by the Glaucoma Staging
System 2, was analysed by means of
linear regression models.
All analyses were performed with
the SAS software version 9.1.3 (SAS
Institute Inc, NC, USA).
Results
Twenty academic and non-academic
ophthalmic centres participated in
this study. Table 1 illustrates the
geographical distribution of the centres
and the accrual by Italian region. From
March 2012 until July 2013, 3227
patients were enrolled in these centres.
The information provided by ﬁfty-eight
patients (1.8%) was incomplete. There-
fore, the statistical analysis was
performed on data from 3169 study
participants.
Tables 2 and 3 summarize the socio-
demographic and clinical characteris-
tics of the participants. A total of
49.8% of participants were females,
and mean age was 66.9 years (SD
12.1). A total of 93.8% patients had a
previous diagnosis of POAG with
median duration of 8.0 years. Median
values (Q1, Q3) for mean deviation
(MD), pattern standard deviation
(PSD) and visual ﬁeld index (VFI) were
3.90 dB (8.50, 1.55), 3.60 dB
(2.01, 6.65) and 93.0 (80.5, 97.5),
respectively. Severity assessment, avail-
able for 3122 patients, showed mild
disease (Stage ≤1) in 31.4% patients
and advanced disease (stage ≥4) in
32.2%. For patients with stage 4 dis-
ease, the range of MD values was 15
to 21 dB and the range of PSD values
was 14 to 20 dB. For patients with stage
5 disease, the MD values were <21 dB
and the PSD values >20 dB.
A total of 97.5% of patients had
received previous medical and/or sur-
gical treatment for glaucoma. Previous
and concomitant treatments are pre-
sented in Table 4.
Overall, 41.2% patients reported at
least one risk factor for glaucoma, the
most common being positive family
history (35.6%). The most frequent
self-reported comorbidities included
systemic hypertension (53.2%) and
hyperlipidaemia (26.2%). Risk factors
Table 4. Previous and concomitant antiglaucoma treatments (N = 3169).
Previous treatment – N (%)*
None 73 (2.5)
Only medical 2113 (71.1)
Only surgical 96 (3.2)
Both medical and surgical 689 (23.2)
Type of previous non-medical treatment – N (%)*
Trabeculectomy 448 (57.1)
Laser (ALT, SLT) 397 (50.6)
Deep sclerectomy 19 (2.4)
Viscocanalostomy 3 (0.4)
Other 21 (2.7)
Number of previous surgeries per patient – N (%)†
1 687 (87.5)
2 93 (11.8)
3 5 (0.6)
Type of previous antiglaucoma drugs – N (%)‡
Prostaglandins 1440 (51.4)
Carbonic anhydrase inhibitor–beta-blocker combination 691 (24.7)
Beta-blockers 691 (24.7)
Prostaglandin–beta-blocker combinations 559 (20.0)
Carbonic anhydrase inhibitors 326 (11.6)
Alpha-agonist–beta-blocker combinations 130 (4.6)
Parasympathomimetic drug 105 (3.7)
Others 7 (0.2)
Number of previous antiglaucoma drugs per patient – N (%)‡
1 1742 (62.2)
2 887 (31.7)
3–5 172 (6.1)
Use of concomitant drugs – N (%) 2197 (69.6)
Type of concomitant drugs – N (%)
Antihypertensive drugs 1538 (48.5)
Statins 587 (18.5)
Endocrine drugs 483 (15.2)
Antiaggregant drugs 406 (12.8)
Diuretics 168 (5.3)
Antiarrhythmics 163 (5.1)
Anticoagulant drugs 131 (4.1)
Cardiovascular drugs 60 (1.9)
Other drugs 363 (11.5)
Number of concomitant drugs per patient – N (%)§
1 999 (45.5)
2–3 982 (44.7)
4–7 216 (9.8)
ALT = Argon laser trabeculoplasty; SLT = Selective laser trabeculoplasty.
* Already diagnosed patients only (n = 2972).
† Patients with previous surgery only (n = 785).
‡ Patients with previous medical treatment only (N = 2802).
§ Patients with concomitant drugs only (n = 2197).
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for glaucoma and systemic conditions
are shown in Fig. 1.
HRQoL scores
Table 5 depicts the subscale and total
scores of the NEI-VFQ-25 question-
naire. The mean total score was 83.6
(SD 15.1). Particularly high scores were
reported in the domains of social func-
tioning (94.1) and dependency (92.0),
while the domains ‘general health’ and
‘general vision’ yielded relatively lower
scores (56.7 and 60.4, respectively).
Table 6 shows the subscale and total
scores for GSS. The total mean score
was 74.9 (SD 19.8). The mean score of
the visual symptoms domain (Func-4)
was 75.9 and that of the non-visual
symptoms domain Symp-6 was 74.9.
Most scales of both questionnaires
showed a ceiling eﬀect (i.e. clustering of
scores at the upper level), with a
consequent reduction in their discrim-
ination power.
HRQoL and glaucoma severity
A clear and highly signiﬁcant associa-
tion (p < 0.001) has been observed
between most subscale and total scores
and the severity of glaucoma, as
expressed by the Glaucoma Staging
System 2 (Figs 2 and 3), with the excep-
tion of the GSS Symp-6 score for non-
visual disturbances (p = 0.1396). The
NEI-VFQ-25 total mean score was
reduced from 92.7 in patients with
glaucoma stage 0–74.3 in patients with
stage 5 disease. The worst aﬀected
domains were ‘general vision’ (69.2 in
stage 0–51.3 in stage 5), near activities
(94.4–71.0) and driving (93.6–68.3).
Correlation between HRQoL instruments
Table 7 summarizes the results of the
correlation analysis. Overall, speciﬁc
GSS subscales showed correlation with
NEI-VFQ-25 subscales designed to
capture similar constructs, but did not
correlate with subscales describing dif-
ferent HRQOL domains. The Symp-6
score highly correlated with the NEI-
VFQ-25 pain subscale (r = 0.624),
which assesses the impact of ocular
pain or discomfort. Func-4 score
showed a large correlation with the
distant activities subscale (r = 0.533).
Discussion
The issue of QoL in patients with
glaucoma has gained considerable
interest in recent years (Glen et al.
2011), but the amount and quality of
information remain incomplete (Mills
et al. 2009).
This is partially due to the fact that the
objective indicators currently employed
to describe glaucoma-related visual
damage, such as visual ﬁelds, may fail
tofullycapturethenegative impactofthe
disease and its treatment on patient
perception of well-being (Odberg et al.
2001b). In fact, the assessment of the
degree of glaucomatous visual ﬁeld loss
that can cause signiﬁcant deterioration
in a patient’s ability to function indepen-
dently (Varma et al. 2010) is not
straightforward. Moreover, HRQoL in
glaucomamay be inﬂuenced bymultiple
factors more generally related to the
burden of the disease and its treatments.
A better understanding of patients’
HRQoL can help clinicians in
customizing disease management and
tailoring treatment and promote guide-
lines regarding patients’ preferences,
daily routine and safety (Glen et al.
2011). We assessed HRQoL and vision-
related QoL in a large sample of
(A)
(B)
Fig. 1. Self-reported risk factors (A) and systemic conditions (B).
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patients treated for glaucoma using the
NEI-VFQ-25 and GSS instruments.
Twenty-one of the 50 clinical centres
caring for the currently diagnosed
500 000 patients with POAG partici-
pated in this study, enrolling 3229
patients. Although the number of
patients from each geographical loca-
tion is imbalanced, it does reﬂect the
diﬀerent population density and med-
ical centre density throughout the
country.
Three diﬀerent types of QoL ques-
tionnaires can be used in a research
setting similar to ours, including gen-
eral health-related QoL, vision-related
QoL and speciﬁc glaucoma-related
QoL. In our study, we opted for two
QoL questionnaires: the NEI-VFQ-25
that evaluates the impact of visual
disorders on a wide range of functional
and self-perceived QoL domains, and
the glaucoma-speciﬁc GSS that scores
the gravity of the visual and non-visual
Table 5. Distribution of National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) scores.
Scale N Mean (SD) Min Q1 Median Q3 Max Floor (%) Ceiling (%)
General health 3165 56.7 (17.9) 0 47.5 60.0 65.0 100 0.9 1.6
General vision 3164 60.4 (16.3) 0 50.0 60.0 70.0 100 0.1 1.0
Ocular pain 3165 77.7 (20.2) 0 62.5 75.0 100 100 0.2 26.4
Near activities 3165 81.9 (20.1) 0 70.8 87.5 100 100 0.1 26.9
Distance activities 3166 87.7 (17.4) 0 83.3 95.8 100 100 0.2 38.7
V-S social functioning 3164 94.1 (13.9) 0 91.7 100 100 100 0.2 74.8
V-S mental health 3165 77.4 (20.8) 0 70.0 85.0 90.0 100 0.3 8.0
V-S role diﬃculties 3159 87.8 (20.5) 0 81.2 100 100 100 0.9 56.4
V-S dependency 3156 92.0 (19.0) 0 93.8 100 100 100 0.6 74.1
Driving 2319 81.0 (24.3) 0 75.0 87.5 100 100 4.3 33.2
Colour vision 3135 94.8 (15.3) 0 100 100 100 100 0.4 86.9
Peripheral vision 3159 85.7 (22.0) 0 75.0 100 100 100 0.4 63.2
Global 3166 83.6 (15.1) 0.4 79.2 89.9 93.4 100 0.1 0.2
SD, Standard deviation; Min, minimum value; Max, maximum value; Q1, 25th percentile; Q3, 75th percentiles; V-S, Vision speciﬁc.
Table 6. Distribution of Glaucoma Symptom Scale (GSS) Questionnaire scores.
Scale N Mean (SD) Min Q1 Median Q3 Max Floor Ceiling
Left eye
Symp-6 3157 74.1 (21.9) 0 62.5 79.2 91.7 100 0.2 18.4
Burning/smarting/stinging 3137 70.8 (35.1) 0 50.0 100 100 100 5.8 55.6
Tearing 3121 77.3 (32.4) 0 50.0 100 100 100 4.6 63.5
Dryness 3123 77.4 (32.8) 0 50.0 100 100 100 4.6 64.5
Itching 3126 73.1 (32.9) 0 50.0 100 100 100 4.5 56.2
Soreness/tiredness 3126 71.9 (33.7) 0 50.0 100 100 100 4.4 55.4
Feeling of something in eye 3120 74.6 (33.0) 0 50.0 100 100 100 4.6 59.4
Func-4 3152 75.9 (24.1) 0 62.5 81.3 100 100 0.4 31.5
Blurry/dim vision 3119 71.5 (34.3) 0 50.0 100 100 100 6.2 55.3
Hard to see in daylight 3122 78.5 (34.7) 0 50.0 100 100 100 7.7 69.7
Hard to see in darkness 3124 74.0 (36.0) 0 50.0 100 100 100 8.9 62.8
Halos around lights 3119 79.7 (31.2) 0 50.0 100 100 100 3.7 67.1
GSS total 3157 74.9 (19.8) 2.5 62.5 77.8 90.0 100 0.1 11.0
Right eye
Symp-6 3156 74.1 (22.0) 0 62.5 79.2 91.7 100 0.3 18.5
Burning/smarting/stinging 3132 71.0 (35.3) 0 50.0 100 100 100 6.2 56.1
Tearing 3128 77.0 (32.9) 0 50.0 100 100 100 5.3 63.5
Dryness 3117 77.3 (32.8) 0 50.0 100 100 100 4.7 64.4
Itching 3126 73.1 (33.0) 0 50.0 100 100 100 4.5 56.2
Soreness/tiredness 3125 71.5 (33.8) 0 50.0 100 100 100 4.5 54.9
Feeling of something in eye 3115 75.0 (32.9) 0 50.0 100 100 100 4.6 59.9
Func-4 3153 75.8 (24.4) 0 62.5 81.3 100 100 0.4 31.6
Blurry/dim vision 3127 71.6 (34.4) 0 50.0 100 100 100 6.5 55.6
Hard to see in daylight 3128 78.1 (35.0) 0 50.0 100 100 100 7.9 69.1
Hard to see in darkness 3125 74.1 (35.9) 0 50.0 100 100 100 8.6 62.8
Halos around lights 3129 79.3 (31.4) 0 50.0 100 100 100 3.8 66.5
GSS total 3156 74.8 (20.0) 2.5 62.5 100 90.0 100 0.1 10.6
Left + right eyes
GSS Symp-6 3161 74.1 (21.2) 0 62.5 78.6 91.7 100 0.2 14.8
GSS Func-4 3160 75.8 (23.4) 0 62.5 81.3 100 100 0.3 28.3
GSS total 3161 74.8 (19.2) 2.5 62.5 78.8 90.0 100 0.1 8.4
SD = Standard deviation; Min = minimum value; Max = maximum value; Q1 = 25th percentile; Q3 = 75th percentiles.
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signs and symptoms of this disease.
Both instruments are self-administered
and have been fully validated in Italian
(Rossi et al. 2003, 2013).
The analysed patient sample had
mild/moderate glaucoma (median
mean deviation: 3.90 dB, median
visual ﬁeld index: 93%); only about a
third of the participants (32.2%) had
advanced glaucoma (stage 4 or 5).
Questionnaire acceptability among
survey participants was excellent both
for GSS and for NEI-VFQ-25. The
percentage of missing item-level
responses was always below 1.7%, with
the exception of the driving subscale of
NEI-VFQ-25, presumably due to the
large proportion of non-drivers among
study participants.
Overall, HRQoL appeared to be
well maintained in our population with
mean scores >70 in most dimensions,
except for general vision and general
health. This ﬁnding reﬂects the fact
that most of our participants had mild
glaucoma and conﬁrms previous ﬁnd-
ings that vision-related QoL remains
relatively intact as long as visual ﬁelds
are not severely aﬀected (McKean-
Cowdin et al. 2008; Labiris et al.
2010; Onakoya et al. 2012; Wolfram
et al. 2013).
Vice versa, the lower scores on gen-
eral health and vision dimensions may
bedue to the advanced age of the studied
population (mean: 66.9, SD: 12.1 years)
or due to the fact that glaucomatous
damage per se can be associated with a
reduction in general health-relatedQoL.
W€andell et al. (1997) used the generic
QoL instrument–Swedish Health-Re-
lated Quality of Life Survey and
observed that, compared to controls,
glaucoma patients with moderate calcu-
lated binocular visual ﬁeld defects had
signiﬁcantly lower scores in 2 of 13
general health and functioning sub-
scales.
Notwithstanding the good overall
results, HRQoL mean total scores, as
well as scores on most subscales of
both instruments, showed a signiﬁcant
inverse association with disease severity
expressed by the Glaucoma staging
system. van Gestel et al. (2010) showed
a similar trend in their cross-sectional
study of 537 ocular hypertension and
POAG patients. Their study found a
relationship between MD and HRQoL
that was independent of patient demo-
graphics, visual acuity, medication
adverse events and surgery.
Fig. 2. NEI-VFQ 25 selected subscale mean scores according to glaucoma severity.
Fig. 3. GSS total and selected subscale mean scores according to glaucoma severity.
Table 7. Spearman correlation between the GSS and the NEI-VFQ-25 scales for each eye.
GSS Symp-6 total GSS Func-4 total GSS Total
NEI-VFQ 25
General health 0.258 0.240 0.292
General vision 0.248 0.408 0.370
Ocular pain 0.624 0.417 0.618
Near activities 0.330 0.483 0.460
Distance activities 0.328 0.533 0.483
Vision-speciﬁc social functioning 0.235 0.392 0.351
Vision-speciﬁc mental health 0.320 0.411 0.418
Vision-speciﬁc role diﬃculties 0.334 0.456 0.453
Vision-speciﬁc dependency 0.224 0.362 0.329
Driving 0.249 0.491 0.410
Colour vision 0.184 0.324 0.287
Peripheral vision 0.266 0.452 0.403
Total mean 0.454 0.592 0.600
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We performed correlation analysis
of the two study instruments using the
Pearson’s correlation coeﬃcient. Speci-
ﬁc GSS subscales showed correlation
with NEI-VFQ-25 subscales designed
to capture similar constructs, but did
not correlate with subscales describing
diﬀerent HRQoL domains. This sug-
gests that the two questionnaires give
complementary, but not overlapping,
information on vision-related QoL of
patients with POAG.
To the best of our knowledge, the
current study represents the largest
investigation on this subject. Many of
the studies on QoL in glaucoma were
conducted in signiﬁcantly smaller sam-
ples. Moreover, as some of these were
designed for the validation of instru-
ments or their translated versions,
rather than the characterization of
vision-related QoL, limited attention
was paid to the representativeness of
the patient populations (Janz et al.
2001; Mangione et al. 2001; Rossi
et al. 2003, 2013; Uenishi et al. 2003;
Labiris et al. 2008, 2010; McKean-
Cowdin et al. 2008; Wang et al. 2008;
Yamagishio et al. 2009; Lin & Yang
2010; Hirneiss et al. 2011; Sawada
et al. 2011; Mbadugha et al. 2012;
Onakoya et al. 2012; Wolfram et al.
2013; Zhou et al. 2013a,b). The large
sample size and wide geographical
distribution suggest that study results
may be representative for the Italian
population of patients treated for
POAG. However, we are unable to
exclude a selection bias towards
patients with less severe disease and
better preserved HRQoL as informa-
tion on individuals who refused partic-
ipation was not collected. Our sample
cannot be considered representative in a
strict methodological sense, because the
practical means of ensuring ‘representa-
tiveness’ (i.e. random inclusion from a
central nationwide registry) are not
available. However, this sample is as
close as pragmatically possible to being
representative by virtue of its wide-
ranging geographical distribution, ori-
gin from diverse academic and non-
academic centres, and size. Further-
more, it is possible that not all included
participants are necessarily patients
with glaucoma. Just as is typical in most
clinical centres, however, these ‘sus-
pects’ are managed in a fashion similar
to patients with glaucoma.
Another possible limitation of the
present study is that it focuses on visual
and daily function, rather than general
health and psychological well-being
aspects of QoL. This was mainly due
to the unavailability of validated
Italian versions of questionnaires
assessing general health and psycho-
logical attributes of QoL. However,
our common experience as members of
the Italian Study Group on QoL in
Glaucoma is that visual and functional
symptoms are major determinants of a
patient’s subjective well-being. This
notion is supported by the results of a
recent study (Skalicky & Goldberg
2008), which showed depression in
patients with glaucoma was associated
with increasing disease severity.
In summary, this study indicated
that self-administered HRQoL instru-
ments are acceptable to patients and
provide detailed information on the
clinical burden of glaucoma and its
eﬀects on visual loss, daily functioning
and other dimensions of HRQoL.
Overall, patient well-being can be pre-
served throughout the early and mod-
erate stages of disease but will decline
with progressive visual loss. These
ﬁndings stress the importance of early
diagnosis and timely and appropriate
therapeutic approaches.
Further analyses are warranted to
better characterize potential additional
factors, which may interfere with
HRQoL in patients with POAG and
to evaluate vision-related functioning
and well-being across diﬀerent stages
of the disease.
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Appendix Italian Study
Group on QoL in glau-
coma
The following persons participated in
this study and are to be considered co-
authors: Co-ordinating Data Centre:
Laboratorio di Ricerca Clinica, IRCCS
Istituto di Ricerche Farmacologiche
‘Mario Negri’, Milano; Statisticians:
IF, ER, A. Roberto; Administrative:
E. Rulli; Informatics Support: L. Cli-
vio, DP, F. Galli, L. Carlucci; Investi-
gators: Universita degli Studi di
Brescia, Brescia (206 patients (pts)):
LQ, AK, I. Riva, L. Delcassi; Univer-
sita degli Studi ‘Magna Graecia’,
Catanzaro (409 pts): LV, T. Carchedi,
S. Talarico; A.O.U. Senese Ospedale
Santa Maria delle Scotte, Universita di
Siena, Siena (337 pts): PF, I. Motolese,
S. A. Bagaglia; Fondazione IRCCS
Istituto di Ricovero e Cura a Carattere
Scientiﬁco Policlinico San Matteo,
Pavia (293 pts): GCMR, S. Lanteri,
L. Bossolesi; IRCCS Istituto di Ricov-
ero e Cura a Carattere Scientiﬁco
Istituto Auxologico Italiano (265 pts):
LC; Universita degli Studi di Torino,
Torino (253 pts): TR, R. Piccini; Fon-
dazione IRCCS Istituto di Ricovero e
Cura a Carattere Scientiﬁco Ca’
Granda Ospedale Maggiore Policlin-
ico, Milano (205 pts): RR, A. Rossi;
A.O.U. di Parma, Parma (200 pts): SG,
V. Tagliavini, N. Ungaro; A.O.U.
Cagliari – Ospedale Civile San Gio-
vanni di Dio, Cagliari (183 pts): MF,
A. Cuccu, I. Zucca; A.O.U. ‘Policlinico
Vittorio Emanuele’ P.O. Gaspare
Rodolico, Catania (126 pts): MU, E.
Bonacci, G. Cardarella; A.O.U. ‘Ospe-
dale Maggiore’, Trieste (114 pts): D.
Tognetto, O. Vattovani, P. Vallon, F.
Iannacone; A.O. Arcispedale Santa
Maria Nuova-IRCCS, Reggio Emilia
(107 pts): L. Fontana, S. Marchi;
Universita Tor Vergata, Fondazione
Policlinico Tor Vergata, Roma (100
pts): G.L. Manni, D. Jannetta, G.
Roberti; A.O. S. Paolo, Milano (100
pts): L. Rossetti, E. Maggiolo, O.
Oneta; A.O.U. Policlinico, Bari (99
pts): C. Sborgia, F. Cantatore;
Ospedale Clinicizzato SS. Annunziata,
Chieti (64 pts): L. Mastropasqua,
L. Agniﬁli; A.O.U. Policlinico
S. Orsola Malpighi, Bologna (36 pts):
E. Campos, C. Gizzi, G. Giannaccare;
A.O. di Desenzano del Garda, Desen-
zano del Garda (BS) (30 pts): V. Pucci,
M. Cassamali; Dipartimento SPES
Universita del Molise Campobasso
(20 pts): C. Costagliola; IRCCS AOU
San Martino – IST, Genova (14 pts):
C. Traverso, R. Scotto, M. Musolino,
L. Landi, A. Bagnis.
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